Supporting Treatment Access and Recovery Through Linkage and Support
Launched by UNIVERSITY OF MASSACHUSETTS, WORCESTER · Jan 27, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Supporting Treatment Access and Recovery Through Linkage and Support," is looking to help people who have both mental health disorders and substance use disorders. The study will involve 208 participants over three years and aims to compare two different types of support: one that includes a comprehensive team approach called MISSION and another that offers support through a Peer Specialist. The goal is to see which method better helps individuals improve their treatment engagement, reduce substance use, and enhance their mental health.
To join this trial, you need to be at least 18 years old and have both a substance use disorder (like problems with alcohol or drugs) and a mental health disorder (such as depression or anxiety). Participants should not be receiving other intensive treatments for these issues at the time. If you join, you can expect to receive either the MISSION approach or the Peer Specialist support, and both methods are designed to help you on your path to recovery. It's important to note that individuals who are in an acute crisis, like being very suicidal or needing immediate medical attention, won't be eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are 18 or older;
- • Have a COD (1 or more substance use disorders (e.g., alcohol and illicit substances), and a mental health disorder (including depression, anxiety, trauma related disorders, bipolar, and/or schizophrenia);
- • Are in the Hub; and
- • Are not engaged in other ongoing multi-component treatment for COD with a behavioral health treatment provider or have not seen their provider for at least 3 months.
- Exclusion Criteria:
- • We will exclude individuals who are acutely psychotic, acutely suicidal with a plan, or homicidal
- • Or with concurrent severe alcohol use disorder or high dose benzodiazepine requiring detoxification.
About University Of Massachusetts, Worcester
The University of Massachusetts Worcester is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the university integrates cutting-edge scientific inquiry with a commitment to improving patient outcomes. Its collaborative approach engages a diverse range of experts, fostering interdisciplinary research that addresses pressing health challenges. With a focus on ethical standards and regulatory compliance, the University of Massachusetts Worcester plays a pivotal role in translating scientific discoveries into practical applications that enhance medical practice and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Worcester, Massachusetts, United States
Worcester, Massachusetts, United States
Patients applied
Trial Officials
David Smelson, PsyD
Principal Investigator
University of Massachusetts, Worcester
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials